{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T18:02:20Z","timestamp":1775152940979,"version":"3.50.1"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background and Objectives<\/jats:title>\n                    <jats:p>Natural history studies in Duchenne muscular dystrophy (DMD) can help to elucidate the trajectory of the disease, understand the importance of clinical milestones, and identify endpoints for clinical trials. We present data from a natural history study of DMD in Chinese individuals with a follow-up of up to 30 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a multicenter, prospective, single-cohort study in Chinese boys of any age with a confirmed diagnosis of DMD. Participants were allocated into one of three groups: Group 1 (ambulatory,\u2009&lt;\u20096 years old); Group 2 (ambulatory,\u2009\u2265\u20096 years old); and Group 3 (non-ambulatory, any age). Endpoints included time to life-altering clinical milestones, North Star Ambulatory Assessment (NSAA; Groups 1 and 2), Performance of Upper Limb 2.0 (PUL2.0; Groups 2 and 3), pulmonary function (Groups 2 and 3), left ventricular ejection fraction (LVEF; Groups 2 and 3), and quality of life endpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>312 participants were enrolled (Group 1, n\u2009=\u200999; Group 2, n\u2009=\u2009177; Group 3, n\u2009=\u200936). Mean (SD) age at baseline in the total study population was 7.9 (3.4) years. Median (95% confidence interval) age at failure to walk in the total study population was 13.1 (12.5\u201314.1) years. Up to 30 months, NSAA total score deteriorated in Group 2 with no decline in Group 1. PUL 2.0 score declined in both Groups 2 and 3. Pulmonary function decreased in Groups 2 and 3 but to a greater extent in Group 3. Changes in LVEF were minimal. Quality of life deteriorated over time, particularly in Group 3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These data extend the 1-year findings from the same study and demonstrate the progression of DMD in Chinese individuals of differing age and ambulatory status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec005\">\n                    <jats:title>Registration information<\/jats:title>\n                    <jats:p>ClinicalTrials.gov identifier: NCT03760029.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0345023","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:29:24Z","timestamp":1775150964000},"page":"e0345023","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["A natural history study of Chinese individuals with Duchenne muscular dystrophy: Results from 2 years of follow-up and beyond"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3957-0110","authenticated-orcid":true,"given":"Xihua","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingzhi","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqi","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangmei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuiqing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying Xu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caiping","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"issue":"1","key":"pone.0345023.ref001","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"D Duan","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"10119","key":"pone.0345023.ref002","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study","volume":"391","author":"CM McDonald","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"pone.0345023.ref003","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.ymthe.2025.04.038","article-title":"Clinical applications of exon-skipping antisense oligonucleotides in neuromuscular diseases","volume":"33","author":"L Torres-Masjoan","year":"2025","journal-title":"Mol Ther"},{"issue":"3","key":"pone.0345023.ref004","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15030778","article-title":"Recent Trends in Antisense Therapies for Duchenne Muscular Dystrophy","volume":"15","author":"H Wilton-Clark","year":"2023","journal-title":"Pharmaceutics"},{"key":"pone.0345023.ref005","first-page":"1","article-title":"The latest developments in synthetic approaches to Duchenne muscular dystrophy","author":"LM Johnson","year":"2025","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"pone.0345023.ref006","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.molmed.2024.01.007","article-title":"HDAC inhibitors as pharmacological treatment for Duchenne muscular dystrophy: a discovery journey from bench to patients","volume":"30","author":"C Mozzetta","year":"2024","journal-title":"Trends Mol Med"},{"issue":"10","key":"pone.0345023.ref007","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/jamaneurol.2022.2480","article-title":"Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial","volume":"79","author":"M Guglieri","year":"2022","journal-title":"JAMA Neurol"},{"issue":"5","key":"pone.0345023.ref008","article-title":"Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled Trial","volume":"102","author":"UJ Dang","year":"2024","journal-title":"Neurology"},{"key":"pone.0345023.ref009","doi-asserted-by":"crossref","first-page":"1167762","DOI":"10.3389\/fcell.2023.1167762","article-title":"Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy","volume":"11","author":"JR Mendell","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"pone.0345023.ref010","article-title":"One year data from ambulatory participants in a phase 1b study of the gene therapy fordadistrogene movaparvovec for Duchenne muscular dystrophy (DMD).","author":"R Butterfield","year":"2022"},{"key":"pone.0345023.ref011","unstructured":"Sarepta Therapeutics Inc. Elevidys\u00ae (delandistrogene moxeparvovec-rokl) prescribing information. https:\/\/www.elevidys.com\/pi. 2024. Accessed 2025 January 28."},{"issue":"6","key":"pone.0345023.ref012","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s13311-023-01423-y","article-title":"Evolving Therapeutic Options for the Treatment of Duchenne Muscular Dystrophy","volume":"20","author":"ES D\u2019Ambrosio","year":"2023","journal-title":"Neurotherapeutics"},{"issue":"9","key":"pone.0345023.ref013","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1474-4422(22)00125-9","article-title":"Emerging therapies for Duchenne muscular dystrophy","volume":"21","author":"T Markati","year":"2022","journal-title":"Lancet Neurol"},{"issue":"11","key":"pone.0345023.ref014","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.nmd.2019.09.010","article-title":"Longitudinal natural history in young boys with Duchenne muscular dystrophy","volume":"29","author":"G Coratti","year":"2019","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"pone.0345023.ref015","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s41669-023-00450-x","article-title":"Developing a Natural History Model for Duchenne Muscular Dystrophy","volume":"8","author":"J Broomfield","year":"2024","journal-title":"Pharmacoecon Open"},{"issue":"1","key":"pone.0345023.ref016","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s13023-021-01862-w","article-title":"The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: a systematic literature review","volume":"16","author":"SM Szabo","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"pone.0345023.ref017","article-title":"Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study","volume":"11","author":"SM Boca","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"pone.0345023.ref018","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/mus.23807","article-title":"The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used","volume":"48","author":"CM McDonald","year":"2013","journal-title":"Muscle Nerve"},{"issue":"4","key":"pone.0345023.ref019","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.nmd.2022.02.009","article-title":"Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls","volume":"32","author":"F Muntoni","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"pone.0345023.ref020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13023-014-0220-7","article-title":"A comprehensive database of Duchenne and Becker muscular dystrophy patients (0-18 years old) in East China","volume":"10","author":"X Li","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"pone.0345023.ref021","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.nmd.2017.02.010","article-title":"Clinical and mutational characteristics of Duchenne muscular dystrophy patients based on a comprehensive database in South China","volume":"27","author":"D-N Wang","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"pone.0345023.ref022","doi-asserted-by":"crossref","first-page":"992546","DOI":"10.3389\/fnins.2022.992546","article-title":"Clinical and genetic characteristics of Chinese Duchenne\/Becker muscular dystrophy patients with small mutations","volume":"16","author":"S Gan","year":"2022","journal-title":"Front Neurosci"},{"issue":"2","key":"pone.0345023.ref023","article-title":"Prevalence and Characteristics of Chinese Patients With Duchenne and Becker Muscular Dystrophy: A Territory Wide Collaborative Study in Hong Kong","volume":"2","author":"SHS Chan","year":"2015","journal-title":"Child Neurol Open"},{"key":"pone.0345023.ref024","first-page":"1866","article-title":"Occurrence rule of major lifetime events of children with Duchenne muscular dystrophy","volume":"27","author":"F Shan","year":"2012","journal-title":"J Applied Clin Pediatr"},{"key":"pone.0345023.ref025","first-page":"100944","article-title":"A 1-year analysis from a natural history study in Chinese individuals with Duchenne muscular dystrophy","volume":"42","author":"X Li","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"issue":"9","key":"pone.0345023.ref026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221097","article-title":"Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy","volume":"14","author":"F Muntoni","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"pone.0345023.ref027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052512","article-title":"24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy","volume":"8","author":"ES Mazzone","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"pone.0345023.ref028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108205","article-title":"Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes","volume":"9","author":"M Pane","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"pone.0345023.ref029","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3233\/JND-221556","article-title":"Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability?","volume":"10","author":"M Pane","year":"2023","journal-title":"J Neuromuscul Dis"},{"issue":"11","key":"pone.0345023.ref030","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.nmd.2018.07.004","article-title":"Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: Long-term natural history with and without glucocorticoids","volume":"28","author":"CM McDonald","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"pone.0345023.ref031","doi-asserted-by":"crossref","first-page":"8823","DOI":"10.3390\/molecules20058823","article-title":"Current understanding of molecular pathology and treatment of cardiomyopathy in duchenne muscular dystrophy","volume":"20","author":"TLE van Westering","year":"2015","journal-title":"Molecules"},{"key":"pone.0345023.ref032","article-title":"The 6-Minute Walk Test and Person-Reported Outcomes in Boys with Duchenne Muscular Dystrophy and Typically Developing Controls: Longitudinal Comparisons and Clinically-Meaningful Changes Over One Year","volume":"5","author":"E Henricson","year":"2013","journal-title":"PLoS Curr"},{"issue":"1","key":"pone.0345023.ref033","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12881-019-0873-0","article-title":"Genetic analysis of 1051 Chinese families with Duchenne\/Becker Muscular Dystrophy","volume":"20","author":"X Kong","year":"2019","journal-title":"BMC Med Genet"},{"issue":"1","key":"pone.0345023.ref034","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-018-0853-z","article-title":"Comprehensive genetic characteristics of dystrophinopathies in China","volume":"13","author":"P Ma","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"pone.0345023.ref035","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13023-021-01837-x","article-title":"Genotype characterization and delayed loss of ambulation by glucocorticoids in a large cohort of patients with Duchenne muscular dystrophy","volume":"16","author":"S Zhang","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"pone.0345023.ref036","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1631\/jzus.B1800541","article-title":"Comprehensive genetic diagnosis of patients with Duchenne\/Becker muscular dystrophy (DMD\/BMD) and pathogenicity analysis of splice site variants in the DMD gene","volume":"20","author":"Y-M Yang","year":"2019","journal-title":"J Zhejiang Univ Sci B"},{"issue":"8","key":"pone.0345023.ref037","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/jhg.2015.43","article-title":"DMD mutation spectrum analysis in 613 Chinese patients with dystrophinopathy","volume":"60","author":"R Guo","year":"2015","journal-title":"J Hum Genet"},{"issue":"4","key":"pone.0345023.ref038","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations","volume":"36","author":"CL Bladen","year":"2015","journal-title":"Hum Mutat"},{"issue":"6","key":"pone.0345023.ref039","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232654","article-title":"Comprehensive genetic analysis of 961 unrelated Duchenne Muscular Dystrophy patients: Focus on diagnosis, prevention and therapeutic possibilities","volume":"15","author":"SH Kumar","year":"2020","journal-title":"PLoS One"},{"issue":"8","key":"pone.0345023.ref040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135189","article-title":"DMD Mutations in 576 Dystrophinopathy Families: A Step Forward in Genotype-Phenotype Correlations","volume":"10","author":"J Juan-Mateu","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"pone.0345023.ref041","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/humu.23953","article-title":"Exonic rearrangements in DMD in Chinese Han individuals affected with Duchenne and Becker muscular dystrophies","volume":"41","author":"C Ling","year":"2020","journal-title":"Hum Mutat"},{"issue":"2","key":"pone.0345023.ref042","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3233\/JND-190447","article-title":"Characterizing Enrollment in Observational Studies of Duchenne Muscular Dystrophy by Race and Ethnicity","volume":"7","author":"AM Barnard","year":"2020","journal-title":"J Neuromuscul Dis"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0345023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:29:32Z","timestamp":1775150972000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0345023"}},"subtitle":[],"editor":[{"given":"Claudia","family":"Brogna","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0345023","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]}}}